What are drug‑eluting stents and bare‑metal (mechanical) stents, and how does the duration of dual antiplatelet therapy differ between them?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Stent Types and DAPT Duration

Both drug-eluting stents (DES) and bare-metal stents (BMS) require at least 12 months of dual antiplatelet therapy (DAPT) in acute coronary syndrome patients, but DES used for stable disease can be safely managed with a minimum of 6 months DAPT, while BMS requires only 1 month in stable patients. 1, 2

Understanding the Two Stent Types

Drug-Eluting Stents (DES):

  • Stents coated with antiproliferative medications (e.g., sirolimus, paclitaxel, everolimus) that prevent tissue overgrowth
  • Dramatically reduce restenosis rates compared to BMS
  • Newer-generation DES (everolimus-eluting, biodegradable polymer) have lower thrombosis risk than first-generation devices
  • Require longer antiplatelet therapy due to delayed vessel healing

Bare-Metal Stents (BMS) / Mechanical Stents:

  • Simple metal scaffolds without drug coating
  • Complete endothelialization occurs within 3-4 weeks 3
  • Higher restenosis rates but lower late thrombosis risk
  • Reserved for patients who cannot tolerate prolonged DAPT (active bleeding, planned surgery, medication nonadherence) 2

DAPT Duration: The Critical Differences

For Acute Coronary Syndrome (ACS) Patients:

Both stent types require ≥12 months DAPT 1, 2

  • Aspirin 75-100 mg daily PLUS
  • P2Y12 inhibitor (clopidogrel 75 mg, prasugrel 10 mg, or ticagrelor 90 mg twice daily)
  • This recommendation applies equally to STEMI and NSTE-ACS patients

For Stable Ischemic Heart Disease:

DES: Minimum 6 months DAPT 2

  • The 2016 ACC/AHA guideline reduced this from the previous 12-month requirement
  • Based on evidence showing newer-generation DES have equivalent safety with shorter duration 1

BMS: Minimum 1 month DAPT 2

  • Shortest required duration due to rapid endothelialization
  • Appropriate when patient cannot commit to longer therapy

The Risk-Benefit Tradeoff of Extended DAPT

Extending DAPT beyond 12 months (to 18-48 months) creates a critical balance 1:

Benefits per 1000 patients/year:

  • 3 fewer stent thromboses
  • 6 fewer myocardial infarctions

Harms per 1000 patients/year:

  • 5 more major bleeding events
  • Weak evidence suggests possible increased mortality 1

When to Consider Extended DAPT (>12 months):

Favor extension if:

  • Prior myocardial infarction (reduces CV death/MI/stroke by 16%, HR 0.84) 1
  • Complex lesions or multiple stents
  • Low bleeding risk
  • Good medication adherence

Avoid extension if:

  • High bleeding risk (e.g., requiring anticoagulation, history of major bleeding)
  • Prior intracranial hemorrhage
  • Planned major surgery
  • Poor medication adherence 2

Critical Pitfalls to Avoid

Never discontinue DAPT prematurely in the early period:

  • Stopping DAPT within the first month after BMS or first 6 months after DES carries catastrophic stent thrombosis risk 2
  • If urgent surgery is needed, weigh bleeding risk against thrombosis risk with cardiology consultation
  • At minimum, continue aspirin perioperatively when possible 3

High bleeding risk patients require special consideration:

  • Recent evidence (2025) suggests short DAPT (≤3 months) with durable polymer DES offers the best efficacy-safety balance in high bleeding risk patients 4
  • Consider stopping P2Y12 inhibitor at 6 months if high bleeding risk develops during treatment 2

Avoid prasugrel in specific populations:

  • Absolute contraindication: prior stroke or TIA 2
  • Use caution in elderly or low body weight patients

The Bottom Line Algorithm

  1. Determine clinical presentation: ACS vs. stable disease
  2. Assess bleeding risk: High vs. standard risk
  3. Select stent type: DES (preferred for most) vs. BMS (only if DAPT duration is problematic)
  4. Apply minimum DAPT duration:
    • ACS + any stent = 12 months
    • Stable + DES = 6 months
    • Stable + BMS = 1 month
  5. Consider extension beyond 12 months only if low bleeding risk AND high ischemic risk (prior MI, complex disease)

The evidence clearly shows that newer-generation DES with appropriately tailored DAPT duration provides superior outcomes for most patients, with BMS reserved as a niche option for those who genuinely cannot receive adequate DAPT duration 1, 2, 5.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.